ReviewMolecular imaging and biology2026
In Vivo Tracking Modalities for Oncolytic Reovirus: Principles, Clinical Applications, and Translational Integration.
Review in Molecular imaging and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOncolytic reovirus, particularly Pelareorep, is a promising cancer therapeutic due to selective replication in Ras-activated tumor cells and immunomodulatory effects. This review aims to critically evaluate current and emerging in vivo tracking strategies, emphasizing translational relevance and clinical implementation. EVIDENCE ACQUISITION: We systematically analyzed preclinical and clinical studies employing optical imaging, nuclear imaging, magnetic resonance imaging, ultrasound/photoacoustic techniques, molecular reporters, and nanoparticle-based platforms. Special focus was placed on integrating functional imaging and molecular assays in Pelareorep trials to monitor viral distribution and therapeutic response.
resultsOptical imaging offers high sensitivity for preclinical investigations; however, it is limited by shallow tissue penetration. Nuclear imaging provides quantitative, whole-body monitoring that is suitable for clinical translation, whereas MRI and ultrasound/photoacoustic modalities enable real-time visualization of both structural and functional aspects. Nanotechnology-based platforms facilitate multimodal imaging and targeted delivery, while molecular tools such as reporter genes, CRISPR-driven circuits, and viral barcoding further enhance spatiotemporal resolution. Clinical trials with Pelareorep demonstrate the feasibility of integrating imaging with molecular assays to evaluate safety, delivery efficiency, and antitumor activity. Persisting challenges include limited genome capacity, immune-mediated clearance, and suboptimal signal penetration.
conclusionEmerging strategies, including synthetic biology reporters, AI-driven image analysis, biosensors, and liquid biopsies, provide scalable, patient-specific tracking solutions. This integrative framework bridges preclinical insights with clinical translation, supporting optimized design, monitoring, and personalization of oncolytic reovirus therapy.
Indexed as
Identifiers
41963749What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.